Mankind Pharma Ltd share Price Today

Pharmaceuticals company Mankind Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

• Revenue from Operations at Rs 2,441 crore, up by 19% YoY
• Domestic revenue at Rs 2,174 crore, up 10% YoY; Exports at Rs 267 crore, up 230% YoY
• EBITDA margin of 24.3%, and PAT margin of 19.5%
• Diluted EPS of Rs 11.7, up by 65% YoY (FV Re.1)

FY24 Financial Highlights:

• Revenue from Operations at Rs 10,335 crore, up by 18%
• Domestic revenue at Rs 9,522 crore, up by 13%; Exports at Rs 813 crore, up by 175%
• EBITDA margin of 24.7%, and PAT margin of 18.8%
• Diluted EPS of Rs 47.7, up by 49% (FV Re.1)
• Cash flow from operations of Rs 2,152 crore, up by 19%
• Net cash balance of Rs 3,260 crore as on 31st March 2024

Rajeev Juneja – Vice Chairman & Managing Director said, “This year, we have achieved a revenue milestone of Rs 10,000 crore. and added 3 more brand families worth over Rs 100 crore raising the total to 23.

Our strong revenue growth of 18% with EBITDA and PAT margin of ~25% and ~19% respectively is supported by an increase in Chronic share to 36% and growth in Modern Trade of over 50%.

We have further strengthened our chronic product portfolio with strategic in-house launches coupled with in-licensing of products like Symbicort – a globally renowned inhaler from Astra Zeneca.

Multiple technology led business transformation projects implemented across functions to further enhance efficiency and productivity laying the foundation for our next phase of growth.”

Result PDF